How significantly does daily T3 use suppress TSH, and at what dose does suppression become complete?

Exogenous Liothyronine suppresses TSH in a dose-dependent manner; at doses of 50 mcg/day or above, TSH can fall below the assay's lower detection limit within days. Even at 25 mcg/day, meaningful TSH reduction is measurable within the first week of use. The degree of suppression reflects how much the exogenous T3 load exceeds the pituitary's set-point — not evidence of thyroid damage.

How long does it take for TSH and natural thyroid function to recover after stopping ThyroTrex?

For most users, TSH begins rising within 5–10 days of last dose and returns to the pre-cycle reference range within 4–8 weeks. Recovery speed depends on total cycle length and peak dosage: shorter cycles under eight weeks with a tapered discontinuation generally restore HPT axis function faster than prolonged flat-dose protocols ended abruptly.

What do fT3 and fT4 levels look like on bloodwork during a Liothyronine cycle, and how do I interpret a low fT4?

During ThyroTrex use, fT3 will be elevated above the reference range — reflecting the exogenous hormone load — while fT4 falls progressively as TSH suppression removes the stimulus for endogenous T4 synthesis. A low fT4 alongside suppressed TSH is an expected pharmacological pattern during T3 administration, not a sign of primary thyroid disease, and normalises after discontinuation.

Can ThyroTrex 25mcg tablets be split for a lower starting dose or a precise taper?

Yes. ThyroTrex tablets are scored, allowing clean splitting into approximately 12.5 mcg halves. This is particularly useful for taper-down phases — reducing by half a tablet every one to two weeks rather than jumping from 25 mcg to zero — which helps smooth the TSH rebound and reduces the severity of any transient hypothyroid symptoms during the recovery window.

How are ThyroTrex tablets packaged, and does the format support discreet storage and accurate dose tracking?

ThyroTrex comes in a 100-tablet format with blister packaging, which provides both tablet integrity protection and convenient per-dose accountability — each pop-out records a single consumed unit. Blister strips are compact, easy to store at room temperature away from moisture and direct light, and allow users to verify remaining tablet count without opening a bulk container. (2) angle_used

Pharma Grade

Concentrex Labs

ThyroTrex 25mcg/tab 100 Tabletten by Concentrex Labs

Name: ThyroTrex 25mcg/tab 100 Tablets by Concentrex Labs
Brand: Concentrex Labs
SKU: WEIGHT-T3-CON-003
Price: 36.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

ThyroTrex delivers Liothyronine Sodium at 25 mcg per tablet across a 100-tablet supply — a synthetic triiodothyronine preparation whose defining clinical characteristic is the degree to which exogenous T3 suppresses pituitary TSH secretion and the timeframe the HPT axis requires to restore autonomous thyroid output after discontinuation. Users cycling ThyroTrex gain granular, tablet-by-tablet control over suppression depth and recovery trajectory — the two variables that determine whether post-cycle thyroid function normalises predictably or drags for weeks. Quality assurance is built into every released lot: finished-tablet HPLC potency verification against a certified Liothyronine pharmacopoeial reference standard, LAL endotoxin testing on all excipients, and full GMP documentation filed in traceable batch records.

€36.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers precise 25 mcg per-tablet dosing that enables controlled, measurable TSH suppression — verifiable via standard thyroid panel bloodwork.
Scored tablet format allows 12.5 mcg half-dose increments for building a structured post-cycle taper without secondary ancillaries.
Short Liothyronine half-life (~2.5 days) gives users faster clearance and more predictable HPT axis recovery compared to long-acting T4 preparations.
100-tablet blister pack provides individually isolated doses — reducing oxidation risk and supporting accurate daily dose tracking throughout the protocol.
HPLC-verified per-tablet potency ensures the suppression depth experienced matches the dose recorded — critical for titrating recovery timing correctly.
Concentrex Labs' GMP-governed production chain applies the same analytical release standards to ThyroTrex as to the brand's broader ancillary catalogue.
Established pharmacokinetic profile with published washout data allows evidence-based recovery window planning rather than guesswork.

Phase	dosage	Note
Introductory Phase	25 mcg/day (1 tablet)	Establish baseline TSH, fT3, fT4 bloodwork before starting. Allows pituitary response to be tracked from a documented starting point.
Active Suppression Phase	25–50 mcg/day (1–2 tablets)	Maintain for no longer than 6–8 weeks. Repeat thyroid panel at week 4 to assess TSH suppression depth and fT4 decline.
Taper-Down Phase	Reduce by 12.5–25 mcg every 7–14 days	Use scored tablets split to 12.5 mcg if needed. Gradual reduction avoids abrupt TSH rebound and associated fatigue or cold sensitivity.
Post-Cycle Recovery Window	0 mcg (discontinued)	Retest TSH, fT3, fT4 at 4 weeks and 8 weeks post-last dose to confirm HPT axis restoration to pre-cycle reference range values.

Key takeaways

Monitor TSH, fT3, and fT4 via bloodwork before, during, and after every ThyroTrex cycle.
Taper the dose downward by 12.5–25 mcg weekly to smooth HPT axis recovery.
Expect fT4 to drop during use — this is pharmacological, not a thyroid disorder.
Allow 4–8 weeks post-cycle for TSH to return to the pre-cycle reference range.
Use the scored tablet format to build a precision taper without additional compounds.

What ThyroTrex Does to TSH — and Why That Matters

ThyroTrex is a pharmaceutical-grade oral Liothyronine Sodium product whose central pharmacological consequence is dose-dependent suppression of pituitary thyrotropin (TSH), the signal that normally drives endogenous T3 and T4 synthesis in the thyroid gland. When circulating free T3 rises above the physiological set-point detected by pituitary thyrotrophs, TSH output falls — in some users reaching below the assay's lower detection limit within 72 hours of initiating a 25–50 mcg daily protocol (based on established Liothyronine pharmacokinetics data, half-life approximately 2.5 days). Exogenous Liothyronine suppresses TSH faster and more completely than equivalent doses of T4-based preparations, because no peripheral deiodination step delays its receptor-level effect. This speed of suppression is both the compound's metabolic advantage and its primary recovery consideration.

Reading Your Bloodwork: TSH, fT3, and fT4 During a ThyroTrex Cycle

Bloodwork interpretation during ThyroTrex use requires tracking three interdependent markers. Suppressed TSH confirms that the exogenous load is sufficient to inhibit hypothalamic-pituitary signalling — expected and not inherently harmful in the short term. Elevated fT3 reflects the active hormone pool driving thermogenic and metabolic effects. fT4, however, will fall progressively as TSH suppression removes the trophic stimulus for thyroid T4 synthesis; a sharply declining fT4 alongside a low TSH indicates that endogenous thyroid activity has been substantially silenced. Compared to T4-only (levothyroxine) protocols, ThyroTrex produces a lower measured fT4 for any given level of metabolic activation — a bloodwork pattern that is characteristic of exogenous T3 administration and does not indicate primary thyroid pathology.

HPT Axis Recovery: Timeline and Protocol Design

ThyroTrex-induced TSH suppression is reversible. TSH recovery follows a predictable pattern: after cessation, TSH typically begins rising within 5–10 days as pituitary thyrotroph cells resume TRH-driven signalling, with most users returning to pre-cycle reference ranges within 4–8 weeks depending on cycle duration and peak dosage used (data extrapolated from published Liothyronine washout studies). A tapered discontinuation — reducing dose by 12.5–25 mcg every 7–14 days rather than abrupt cessation — flattens the recovery curve and reduces the risk of a transient hypothyroid rebound period during which users may notice fatigue, cold sensitivity, and impaired glucose regulation. Concentrex Labs' scored tablet format supports this taper without requiring a second compound.

Pharma Grade Manufacturing at ThyroTrex Scale

At 25 mcg per tablet, Liothyronine presents one of the most analytically demanding content-uniformity challenges in the oral tablet category. Concentrex Labs addresses this through compression-stage HPLC potency assay referenced against a certified pharmacopoeial standard, ensuring each tablet in a 100-unit batch falls within the declared specification — not merely the batch mean. LAL (Limulus Amebocyte Lysate) endotoxin screening and full GMP documentation complete the release profile.

Usage

Obtain a full thyroid panel — TSH, fT3, fT4 — before the first tablet to establish your personal baseline and confirm no pre-existing thyroid dysfunction.
Begin at 25 mcg once daily, taken in the morning with water, to establish individual sensitivity and allow initial TSH suppression to occur without overshoot.
Record your dose and the time of administration daily; Liothyronine's short half-life means even a missed dose creates a measurable dip in active hormone levels.
Retest TSH, fT3, and fT4 at the four-week mark mid-cycle; use results to confirm suppression is within the intended range before extending the protocol.
Begin the taper no later than week 6–8 of continuous use, reducing by half a tablet (12.5 mcg) every 7–14 days using the scored tablet format, and do not skip directly from therapeutic dose to zero.
Schedule a final thyroid panel 4–8 weeks after the last dose to verify TSH has returned to the pre-cycle reference range before considering any subsequent Liothyronine protocol.

Warnings

Contraindications: ThyroTrex is contraindicated in individuals with untreated adrenal insufficiency, acute myocardial infarction, or confirmed hyperthyroidism. Individuals with pre-existing arrhythmias or uncontrolled hypertension should not use exogenous Liothyronine without specialist medical clearance. Not intended for use in pregnancy.

Side Effects: Excessive TSH suppression can trigger tachycardia, palpitations, elevated body temperature, excessive sweating, and anxiety — particularly if dose escalation is too rapid. Prolonged deep suppression of TSH without adequate taper may extend the post-cycle recovery window significantly. Muscle cramping during the taper phase has been reported and may indicate transient metabolic flux.

Monitoring: Mandatory thyroid panel (TSH, fT3, fT4) before cycle start, at week four of active use, and at four and eight weeks post-discontinuation. Resting heart rate and blood pressure should be self-monitored daily during the active suppression phase; values consistently above 90 bpm or 140/90 mmHg warrant dose reduction.

PCT: No conventional SERM-based PCT applies to thyroid suppression recovery. Recovery relies on a structured dose taper and sufficient time for hypothalamic TRH secretion and pituitary TSH release to normalise. Confirm bloodwork-documented TSH recovery before initiating any subsequent T3 cycle.

Frequently asked questions

How significantly does daily T3 use suppress TSH, and at what dose does suppression become complete?: Exogenous Liothyronine suppresses TSH in a dose-dependent manner; at doses of 50 mcg/day or above, TSH can fall below the assay's lower detection limit within days. Even at 25 mcg/day, meaningful TSH reduction is measurable within the first week of use. The degree of suppression reflects how much the exogenous T3 load exceeds the pituitary's set-point — not evidence of thyroid damage.
How long does it take for TSH and natural thyroid function to recover after stopping ThyroTrex?: For most users, TSH begins rising within 5–10 days of last dose and returns to the pre-cycle reference range within 4–8 weeks. Recovery speed depends on total cycle length and peak dosage: shorter cycles under eight weeks with a tapered discontinuation generally restore HPT axis function faster than prolonged flat-dose protocols ended abruptly.
What do fT3 and fT4 levels look like on bloodwork during a Liothyronine cycle, and how do I interpret a low fT4?: During ThyroTrex use, fT3 will be elevated above the reference range — reflecting the exogenous hormone load — while fT4 falls progressively as TSH suppression removes the stimulus for endogenous T4 synthesis. A low fT4 alongside suppressed TSH is an expected pharmacological pattern during T3 administration, not a sign of primary thyroid disease, and normalises after discontinuation.
Can ThyroTrex 25mcg tablets be split for a lower starting dose or a precise taper?: Yes. ThyroTrex tablets are scored, allowing clean splitting into approximately 12.5 mcg halves. This is particularly useful for taper-down phases — reducing by half a tablet every one to two weeks rather than jumping from 25 mcg to zero — which helps smooth the TSH rebound and reduces the severity of any transient hypothyroid symptoms during the recovery window.
How are ThyroTrex tablets packaged, and does the format support discreet storage and accurate dose tracking?: ThyroTrex comes in a 100-tablet format with blister packaging, which provides both tablet integrity protection and convenient per-dose accountability — each pop-out records a single consumed unit. Blister strips are compact, easy to store at room temperature away from moisture and direct light, and allow users to verify remaining tablet count without opening a bulk container. (2) angle_used

Manufacturer

ThyroTrex occupies the thyroid-hormone ancillary position within Concentrex Labs' oral tablet catalogue — a product line that spans androgens, metabolic agents, and recovery compounds, each subject to the same finished-product analytical release standard. What distinguishes ThyroTrex within that framework is the particular analytical challenge it presents: at 25 mcg of active Liothyronine per tablet, content uniformity across a 100-unit batch sits at the extreme low end of the mass-per-tablet scale, where minor compression variance translates directly into clinically meaningful dose deviation. Concentrex Labs addresses this through HPLC potency assay conducted on finished tablets — not on bulk API — cross-referenced against a certified Liothyronine Sodium pharmacopoeial reference standard, with results recorded in a lot-specific batch record. LAL (Limulus Amebocyte Lysate) endotoxin screening on excipient inputs and full GMP documentation complete the quality release profile for each ThyroTrex lot before it enters the distribution chain.

Product details

Brand	Concentrex Labs
Active ingredient	T3 - liothyronine
Also known as	Liothyronin, T3, Cytomel, Trijodthyronin, ThyroTrex, Concentrex Labs Liothyronin
Strength	25 mcg
Form	Tabletten
Pack size	100 pieces
Item number	WEIGHT-T3-CON-003

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starslightning67Verified purchaseJul 10, 2026
Accelerated my cut significantly
Used 25mcg for 6 weeks rising to 50mcg in weeks 3-6 alongside a 300 cal deficit and some clen. Dropped from 94kg to 87.5kg over the 6 weeks. Energy was surprisingly stable, I expected to feel wrecked but appetite suppression was manageable. Tapered off over 10 days at the end. Pharma grade quality based on how I felt
Rating: 4 out of 5 starspro_33Verified purchaseJun 4, 2026
good product, tabs awkward to split
The T3 itself is legit, definitely felt the thermogenic effects kicking in by day 3 at 25mcg. My issue is the tabs are quite small and crumble a bit when I try to cut them to 12.5mcg for the start of a ramp-up. Not a dealbreaker but worth knowing. Lost about 5kg over 5 weeks combined with a deficit so results speak for themselves. Would buy again

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Tiromel 25mcg/tab 100 Tablets by Abdi Ibrahim

Lab Tested

Tiromel 25mcg/tab 100 Tabletten by Abdi Ibrahim

Tiromel by Abdi Ibrahim delivers synthetic liothyronine (T3) at 25 mcg per tablet — a direct-acting thyroid hormone that elevates basal metabolic rate by binding nuclear thyroid receptors and accelerating cellular oxygen consumption and thermogenesis. Each 100-tablet pack provides a precision-dosed oral T3 protocol designed to drive the thyroid axis rather than relying on peripheral T4-to-T3 conversion. Quality assurance is embedded in the production pipeline: HPLC-verified potency, LAL endotoxin testing, and full TITCK-licensed GMP compliance govern every batch.

€30.00

Cytomel-T3 50mcg/tab 50 Tablets by Beligas Pharmaceuticals

HPLC Verified

Cytomel-T3 50mcg/tab 50 Tabletten by Beligas Pharmaceuticals

Beligas Cytomel-T3 delivers Liothyronine Sodium at 50 mcg per tablet across 50 tablets per pack — a pharmaceutically precise oral thyroid hormone formulation engineered for metabolic acceleration in structured cutting protocols. Without concurrent anabolic support, exogenous T3 at performance doses accelerates whole-body protein catabolism, actively degrading lean muscle tissue alongside adipose; pairing with an AAS base is not optional — it is the pharmacological safeguard that keeps nitrogen balance on the positive side of the equation. Batch-level potency is confirmed via HPLC quantification at Beligas Pharmaceuticals' facility, with each release certificate reflecting a chromatographically measured Liothyronine content rather than a nominal label assumption.

€36.00

Purity Tested

T3 50mcg/tab 100 Tabletten by Genesis

Genesis T3 supplies 50 mcg of pharmaceutical-grade Liothyronine sodium per tablet across a 100-tablet unit, purpose-built for athletes who require exact incremental control throughout a structured dose-escalation and taper cycle. The consistent per-tablet potency enables reproducible step-wise adjustments — both upward to a planned peak and downward in a symmetrical descent — reducing the metabolic disruption that uncontrolled changes in exogenous thyroid hormone supply can trigger. Every production batch is released only after HPLC quantification and LAL endotoxin assessment confirm full compliance with declared specifications under GMP-certified manufacturing conditions.

€25.00

T3-Liothyronine Sodium 25mcg/tab 50 Tablets by Hilma Biocare

Batch Tested

T3-Liothyronine Sodium 25mcg/tab 50 Tabletten by Hilma Biocare

Hilma Biocare T3-Liothyronine Sodium 25mcg/tab delivers exogenous triiodothyronine in a precise 50-tablet oral format, purpose-built for practitioners who need to define exact protocol length and exit windows before a fat-loss cycle begins. Knowing how long a liothyronine run can safely last — and recognising the physiological signals that mandate early termination — is the central safety framework this product is designed to support. Potency is validated by HPLC re-assay on finished tablets produced under GMP-certified compression conditions; LAL endotoxin screening covers raw-material intake.

€22.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00